Last quarter (Q2 2023), TransCode Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, TransCode Therapeutics's net income was $-4.34M. See TransCode Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	$ 8.80M	$ 18.67M	$ -6.15M	$ 726.60K	$ 456.87K
Operating Income	$ -19.86M	$ -18.67M	$ -6.15M	$ -726.60K	$ -456.87K
Net Non Operating Interest Income Expense	$ 486.83K	$ 20.41K	$ 183.93K	$ -394.44K	$ -156.93K
Other Income Expense	$ -788.94K	$ -1.08M	$ 9.19K	$ -1.22M	$ 6.58K
Pretax Income	$ -18.58M	$ -17.56M	$ -5.98M	$ -2.34M	$ -607.21K
Tax Provision	-	-	$ -53.05K	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -18.58M	$ -17.56M	$ -5.98M	$ -1.95M	$ -450.25K
Basic EPS	$ -4.34	$ -1.35	$ -0.81	$ -0.32	$ -0.09
Diluted EPS	$ -4.34	$ -1.35	$ -0.81	$ -0.32	$ -0.09
Basic Average Shares	$ 41.67M	$ 12.98M	$ 8.43M	$ 6.04M	$ 5.13M
Diluted Average Shares	$ 41.67M	$ 12.98M	$ 8.43M	$ 6.04M	$ 5.13M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 8.80M	$ 18.67M	$ -6.15M	$ 726.60K	$ 456.87K
Net Income From Continuing And Discontinued Operation	$ -18.58M	$ -17.56M	$ -5.98M	$ -2.34M	$ -607.21K
Normalized Income	$ -7.72M	$ -13.88M	-	$ -1.12M	$ -613.80K
Interest Expense	-	-	-	$ 394.57K	$ 156.97K
EBIT	$ -19.06M	$ -17.56M	$ -6.16M	$ -1.95M	$ -450.25K
EBITDA	$ -14.56M	$ -17.47M	$ -6.12M	$ -1.95M	$ -450.25K

Currency in USD

TransCode Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing